What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
His primary areas of study are Internal medicine, Renal cell carcinoma, Carcinoma, Surgery and Oncology.
His Internal medicine research includes elements of Gastroenterology and Immunology.
His study in Renal cell carcinoma is interdisciplinary in nature, drawing from both Bevacizumab, Progression-free survival and Phases of clinical research.
His Carcinoma study combines topics from a wide range of disciplines, such as Clinical trial and Survival analysis.
He interconnects Androgen deprivation therapy, Prostate cancer, Axitinib and Everolimus in the investigation of issues within Surgery.
Alain Ravaud has researched Oncology in several fields, including Biomarker, Progressive disease, Atezolizumab and Hazard ratio.
His most cited work include:
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma (3172 citations)
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2410 citations)
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (1907 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Renal cell carcinoma, Sunitinib and Surgery.
His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine.
His Oncology research integrates issues from Bevacizumab, Targeted therapy, Clinical trial and Atezolizumab.
His studies in Renal cell carcinoma integrate themes in fields like Nephrectomy, Carcinoma, Pharmacology and Urology.
Alain Ravaud combines subjects such as Sorafenib, Clear cell renal cell carcinoma, Adjuvant, Tyrosine-kinase inhibitor and Hazard ratio with his study of Sunitinib.
His research in Phases of clinical research and Clinical endpoint are components of Surgery.
He most often published in these fields:
- Internal medicine (67.80%)
- Oncology (48.80%)
- Renal cell carcinoma (40.40%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (67.80%)
- Oncology (48.80%)
- Renal cell carcinoma (40.40%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Renal cell carcinoma, Sunitinib and Adverse effect.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
His Oncology research incorporates themes from Progressive disease, Chemotherapy, Phases of clinical research, Atezolizumab and Randomized controlled trial.
His work carried out in the field of Phases of clinical research brings together such families of science as Clinical endpoint and Carcinoma.
His Renal cell carcinoma research incorporates elements of Adjuvant, Primary tumor, First line and Ipilimumab.
His research in Sunitinib intersects with topics in Vascular endothelial growth factor, Clear cell renal cell carcinoma, Kidney cancer, Everolimus and Nephrectomy.
Between 2018 and 2021, his most popular works were:
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (302 citations)
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. (116 citations)
- The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. (85 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
Alain Ravaud focuses on Internal medicine, Oncology, Sunitinib, Renal cell carcinoma and Confidence interval.
Internal medicine is closely attributed to Gastroenterology in his study.
His Oncology study incorporates themes from Progressive disease, Chemotherapy, Wilms' tumor and Hazard ratio.
His Sunitinib research is multidisciplinary, incorporating elements of Atezolizumab, Adjuvant, Nephrectomy, Bevacizumab and Ipilimumab.
Alain Ravaud works mostly in the field of Renal cell carcinoma, limiting it down to topics relating to Nivolumab and, in certain cases, Tivozanib, Family medicine and Objective response.
As a part of the same scientific family, Alain Ravaud mostly works in the field of Confidence interval, focusing on Urology and, on occasion, Phases of clinical research, Papillary renal cell carcinomas, Axitinib, Regimen and No-observed-adverse-effect level.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
